secwatch / observer
8-K filed October 2, 2023, 7:59 PM ET ticker BJDX CIK 0001704287
leadership confidence high sentiment neutral materiality 0.60

Bluejay Diagnostics CFO Kenneth Fisher departs; Frances Scally named interim CFO

Bluejay Diagnostics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kenneth R. Fisher

Chief Financial Officer
BJDX · Bluejay Diagnostics, Inc.
Effective
2023-09-26
Successor
Frances Scally
Filed
October 2, 2023, 7:59 PM ET
On September 26, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Kenneth R. Fisher agreed that Mr. Fisher would depart the Company as an employee and cease serving as its Chief Financial Officer (“CFO”).
Appointed

Scott Levy

special advisor to the CEO
BJDX · Bluejay Diagnostics, Inc.
Effective
2023-09-26
Filed
October 2, 2023, 7:59 PM ET
Under the these agreements, Scott Levy will complement Ms. Scally as a special advisor to the Company’s CEO.
Appointed (interim)

Frances Scally

Chief Financial Officer
BJDX · Bluejay Diagnostics, Inc.
Effective
2023-09-26
Filed
October 2, 2023, 7:59 PM ET
On September 26, 2023, the Board of Directors (the “Board”) of the Company appointed Frances Scally, age 56, as interim CFO of the Company and designated her as the Company’s principal financial officer and principal accounting officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth R. Fisher departed as Chief Financial Officer at Bluejay Diagnostics, Inc..

Action
departed
Role
Chief Financial Officer
Exact text from the filing
On September 26, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Kenneth R. Fisher agreed that Mr. Fisher would depart the Company as an employee and cease serving as its Chief Financial Officer (“CFO”).
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.8

Scott Levy was appointed as special advisor to the CEO at Bluejay Diagnostics, Inc..

Action
appointed
Role
special advisor to the CEO
Exact text from the filing
Under the these agreements, Scott Levy will complement Ms. Scally as a special advisor to the Company’s CEO.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Frances Scally was appointed as Chief Financial Officer at Bluejay Diagnostics, Inc..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
On September 26, 2023, the Board of Directors (the “Board”) of the Company appointed Frances Scally, age 56, as interim CFO of the Company and designated her as the Company’s principal financial officer and principal accounting officer, effective immediately.
View on SEC.gov

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR
accession 0001013762-23-000463
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.